Literature DB >> 32692113

Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.

Alyssa Vecchio1, Kevin Robertson1, Deanna Saylor2, Gertrude Nakigozi3, Noeline Nakasujja4, Alice Kisakye4, James Batte4, Richard Mayanja4, Aggrey Anok4, Steven J Reynolds5, Thomas C Quinn5,6, Ronald Gray7, Maria J Wawer7, Ned Sacktor2, Leah H Rubin2,7,8.   

Abstract

BACKGROUND: HIV-associated neurocognitive disorders remain prevalent despite effective antiretroviral therapy (ART), but there are limited longitudinal data on people living with HIV (PLWH) in sub-Saharan Africa. We examined neuropsychological (NP) performance in PLWH in a longitudinal study in Uganda.
METHODS: Participants enrolled through the Rakai Community Cohort Study (400 ART-naive PLWH and 400 matched HIV-negative persons) were administered NP assessments. In 2017, PLWH who had initiated ART underwent a 2-year follow-up assessment. Demographically adjusted Z-scores for each NP test were established using data from the HIV- controls. Multivariable linear and logistic regressions were conducted to examine group differences in NP performance. Mixed-effects regressions were conducted to examine ART-related changes in NP outcomes.
RESULTS: Of 333 PLWH who returned for their 2-year follow-up visit, 312 (94%) had initiated ART. Those on ART had a mean age of 35.6 years (SD ± 8.5 years) and mean education of 5.4 years (SD ± 3.3 years); 49% were women. ART-associated NP improvements occurred in verbal learning and memory (P's < 0.05), motor (P's < 0.01), and some measures of processing speed (P = 0.002), whereas there were declines in attention/working memory (P's < 0.001) and semantic fluency (P < 0.001). Pre-ART CD4 count and efavirenz use were associated with a more impaired change in NP performance.
CONCLUSIONS: PLWH in this resource-limited setting showed improved neurocognitive performance on most NP tests after ART initiation. However, the declines in attention/working memory and fluency performance, as well as relationship to efavirenz, warrant further study.

Entities:  

Year:  2020        PMID: 32692113     DOI: 10.1097/QAI.0000000000002385

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  4 in total

Review 1.  Neuroimmunology of CNS HIV Infection: A Narrative Review.

Authors:  Ana-Claire Meyer; Alfred Kongnyu Njamnshi; Magnus Gisslen; Richard W Price
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

2.  Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda.

Authors:  Alyssa C Vecchio; Dionna W Williams; Yanxun Xu; Danyang Yu; Deanna Saylor; Sarah Lofgren; Riley O'Toole; David R Boulware; Noeline Nakasujja; Gertrude Nakigozi; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor; Leah H Rubin
Journal:  Brain Behav Immun       Date:  2020-12-24       Impact factor: 7.217

3.  Immunometabolic Reprogramming in Response to HIV Infection Is Not Fully Normalized by Suppressive Antiretroviral Therapy.

Authors:  Pragney Deme; Leah H Rubin; Danyang Yu; Yanxun Xu; Gertrude Nakigozi; Noeline Nakasujja; Aggrey Anok; Alice Kisakye; Thomas C Quinn; Steven J Reynolds; Richard Mayanja; James Batte; Maria J Wawer; Ned C Sacktor; Deanna Saylor; Norman J Haughey
Journal:  Viruses       Date:  2022-06-15       Impact factor: 5.818

4.  Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.

Authors:  Noeline Nakasujja; Alyssa C Vecchio; Deanna Saylor; Sarah Lofgren; Gertrude Nakigozi; David R Boulware; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Steven J Reynolds; Thomas C Quinn; Carlos A Pardo; Anupama Kumar; Ronald H Gray; Maria J Wawer; Ned Sacktor; Leah H Rubin
Journal:  J Neurovirol       Date:  2021-07-31       Impact factor: 3.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.